APO RESEARCH · REPORT
Nicotinamide Mononucleotide (NMN)
Nicotinamide Mononucleotide (NMN) is a molecule naturally found in the body and is a precursor to nicotinamide adenine dinucleotide (NAD+), which plays a crucial role in various cellular processes. NAD+ is involved in energy metabolism, DNA repair, gene expression, and cell signaling.
Product & engineering
Understand the product.
Nicotinamide Mononucleotide (NMN) is a molecule naturally found in the body and is a precursor to nicotinamide adenine dinucleotide (NAD+), which plays a crucial role in various cellular processes. NAD+ is involved in energy metabolism, DNA repair, gene expression, and cell signaling.
NMN is considered a promising compound in anti-aging research due to its role in boosting NAD+ levels. As humans age, NAD+ levels tend to decline, which may contribute to age-related health issues. By supplementing with NMN, it's hypothesized that NAD+ levels can be replenished, potentially slowing down the aging process and improving overall health.
Selected research
Market Outlook & Growth Opportunities
Global Nicotinamide Mononucleotide (NMN) Market Outlook and Growth Opportunities 2026
Market perspective
Nicotinamide Mononucleotide (NMN) is a molecule naturally found in the body and is a precursor to nicotinamide adenine dinucleotide (NAD+), which plays a crucial role in various cellular processes. NAD+ is involved in energy metabolism, DNA repair, gene expression, and cell signaling.
NMN is considered a promising compound in anti-aging research due to its role in boosting NAD+ levels. As humans age, NAD+ levels tend to decline, which may contribute to age-related health issues. By supplementing with NMN, it's hypothesized that NAD+ levels can be replenished, potentially slowing down the aging process and improving overall health.
The global Nicotinamide Mononucleotide (NMN) market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.
Read the full market overview
The North America market for Nicotinamide Mononucleotide (NMN) is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
The Europe market for Nicotinamide Mononucleotide (NMN) is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
The Asia Pacific market for Nicotinamide Mononucleotide (NMN) is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
In China, the Nicotinamide Mononucleotide (NMN) market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Major global companies in the Nicotinamide Mononucleotide (NMN) market include GeneHarbor, Herbalmax, Genex Formulas, MIRAILAB BIOSCIENCE Inc, Maac10 Formulas, EffePharm, Bontac, CELFULL and Kingdomway, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
This report provides an overview of the global Nicotinamide Mononucleotide (NMN) market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.
The study covers key producers of Nicotinamide Mononucleotide (NMN) and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.
The report also presents Nicotinamide Mononucleotide (NMN) sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.
In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Nicotinamide Mononucleotide (NMN) market size, projected growth trends, production technologies, key applications, and end-use industries.
Nicotinamide Mononucleotide (NMN) Segment by Company
GeneHarbor
Herbalmax
Genex Formulas
MIRAILAB BIOSCIENCE Inc
Maac10 Formulas
EffePharm
Bontac
CELFULL
Kingdomway
Oriental Yeast
Blue California (Conagen)
Borealis Pharma B.V. (Longevir®)
Nicotinamide Mononucleotide (NMN) Segment by Type
Content Greater than or Equal to 98%
Content Less than 98%
Nicotinamide Mononucleotide (NMN) Segment by Application
Health Care Products
Cosmetics
Others
Nicotinamide Mononucleotide (NMN) Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Study Objectives
1. To analyze and research the global Nicotinamide Mononucleotide (NMN) status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions Nicotinamide Mononucleotide (NMN) market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify Nicotinamide Mononucleotide (NMN) significant trends, drivers, influence factors in global and regions.
6. To analyze Nicotinamide Mononucleotide (NMN) competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Nicotinamide Mononucleotide (NMN) market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Nicotinamide Mononucleotide (NMN) and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Nicotinamide Mononucleotide (NMN).
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Provides an overview of the Nicotinamide Mononucleotide (NMN) market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).
Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Nicotinamide Mononucleotide (NMN) industry.
Chapter 3: Detailed analysis of Nicotinamide Mononucleotide (NMN) manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales and value of Nicotinamide Mononucleotide (NMN) in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 7: Sales and value of Nicotinamide Mononucleotide (NMN) in country level. It provides sigmate data by type, and by application for each country/region.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Concluding Insights.
More report detail
Tables and figures
Scope & coverage.
Types
- Content Greater than or Equal to 98%
- Content Less than 98%
Applications
- Health Care Products
- Cosmetics
- Others
Companies covered
- GeneHarbor
- Herbalmax
- Genex Formulas
- MIRAILAB BIOSCIENCE Inc
- Maac10 Formulas
- EffePharm
- Bontac
- CELFULL
- Kingdomway
- Oriental Yeast
- Blue California (Conagen)
- Borealis Pharma B.V. (Longevir®)
Inside the report.
1 Market Overview
- 1.1 Product Definition
- 1.2 Global Market Growth Prospects
- 1.2.1 Global Nicotinamide Mononucleotide (NMN) Sales Value (2021-2032)
- 1.2.2 Global Nicotinamide Mononucleotide (NMN) Sales Volume (2021-2032)
- 1.2.3 Global Nicotinamide Mononucleotide (NMN) Sales Average Price (2021-2032)
- 1.3 Assumptions and Limitations
- 1.4 Study Goals and Objectives
2 Nicotinamide Mononucleotide (NMN) Market Dynamics
- 2.1 Nicotinamide Mononucleotide (NMN) Industry Trends
- 2.2 Nicotinamide Mononucleotide (NMN) Industry Drivers
- 2.3 Nicotinamide Mononucleotide (NMN) Industry Opportunities and Challenges
- 2.4 Nicotinamide Mononucleotide (NMN) Industry Restraints
3 Nicotinamide Mononucleotide (NMN) Market by Company
- 3.1 Global Nicotinamide Mononucleotide (NMN) Company Revenue Ranking in 2025
- 3.2 Global Nicotinamide Mononucleotide (NMN) Revenue by Company (2021-2026)
- 3.3 Global Nicotinamide Mononucleotide (NMN) Sales Volume by Company (2021-2026)
- 3.4 Global Nicotinamide Mononucleotide (NMN) Average Price by Company (2021-2026)
- 3.5 Global Nicotinamide Mononucleotide (NMN) Company Ranking (2024-2026)
- 3.6 Global Nicotinamide Mononucleotide (NMN) Company Manufacturing Base and Headquarters
- 3.7 Global Nicotinamide Mononucleotide (NMN) Company Product Type and Application
- 3.8 Global Nicotinamide Mononucleotide (NMN) Company Establishment Date
- 3.9 Market Competitive Analysis
- 3.9.1 Global Nicotinamide Mononucleotide (NMN) Market Concentration Ratio (CR5 and HHI)
- 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
- 3.9.3 2025 Nicotinamide Mononucleotide (NMN) Tier 1, Tier 2, and Tier 3 Companies
- 3.10 Mergers and Acquisitions Expansion
4 Nicotinamide Mononucleotide (NMN) Market by Type
- 4.1 Nicotinamide Mononucleotide (NMN) Type Introduction
- 4.1.1 Content Greater than or Equal to 98%
- 4.1.2 Content Less than 98%
- 4.2 Global Nicotinamide Mononucleotide (NMN) Sales Volume by Type
- 4.2.1 Global Nicotinamide Mononucleotide (NMN) Sales Volume by Type (2021 VS 2025 VS 2032)
- 4.2.2 Global Nicotinamide Mononucleotide (NMN) Sales Volume by Type (2021-2032)
- 4.2.3 Global Nicotinamide Mononucleotide (NMN) Sales Volume Share by Type (2021-2032)
- 4.3 Global Nicotinamide Mononucleotide (NMN) Sales Value by Type
- 4.3.1 Global Nicotinamide Mononucleotide (NMN) Sales Value by Type (2021 VS 2025 VS 2032)
- 4.3.2 Global Nicotinamide Mononucleotide (NMN) Sales Value by Type (2021-2032)
- 4.3.3 Global Nicotinamide Mononucleotide (NMN) Sales Value Share by Type (2021-2032)
5 Nicotinamide Mononucleotide (NMN) Market by Application
- 5.1 Nicotinamide Mononucleotide (NMN) Application Introduction
- 5.1.1 Health Care Products
- 5.1.2 Cosmetics
- 5.1.3 Others
- 5.2 Global Nicotinamide Mononucleotide (NMN) Sales Volume by Application
- 5.2.1 Global Nicotinamide Mononucleotide (NMN) Sales Volume by Application (2021 VS 2025 VS 2032)
- 5.2.2 Global Nicotinamide Mononucleotide (NMN) Sales Volume by Application (2021-2032)
- 5.2.3 Global Nicotinamide Mononucleotide (NMN) Sales Volume Share by Application (2021-2032)
- 5.3 Global Nicotinamide Mononucleotide (NMN) Sales Value by Application
- 5.3.1 Global Nicotinamide Mononucleotide (NMN) Sales Value by Application (2021 VS 2025 VS 2032)
- 5.3.2 Global Nicotinamide Mononucleotide (NMN) Sales Value by Application (2021-2032)
- 5.3.3 Global Nicotinamide Mononucleotide (NMN) Sales Value Share by Application (2021-2032)
6 Nicotinamide Mononucleotide (NMN) Regional Sales and Value Analysis
- 6.1 Global Nicotinamide Mononucleotide (NMN) Sales by Region: 2021 VS 2025 VS 2032
- 6.2 Global Nicotinamide Mononucleotide (NMN) Sales by Region (2021-2032)
- 6.2.1 Global Nicotinamide Mononucleotide (NMN) Sales by Region: 2021-2026
- 6.2.2 Global Nicotinamide Mononucleotide (NMN) Sales by Region (2027-2032)
- 6.3 Global Nicotinamide Mononucleotide (NMN) Sales Value by Region: 2021 VS 2025 VS 2032
- 6.4 Global Nicotinamide Mononucleotide (NMN) Sales Value by Region (2021-2032)
- 6.4.1 Global Nicotinamide Mononucleotide (NMN) Sales Value by Region: 2021-2026
- 6.4.2 Global Nicotinamide Mononucleotide (NMN) Sales Value by Region (2027-2032)
- 6.5 Global Nicotinamide Mononucleotide (NMN) Market Price Analysis by Region (2021-2026)
- 6.6 North America
- 6.6.1 North America Nicotinamide Mononucleotide (NMN) Sales Value (2021-2032)
- 6.6.2 North America Nicotinamide Mononucleotide (NMN) Sales Value Share by Country, 2025 VS 2032
- 6.7 Europe
- 6.7.1 Europe Nicotinamide Mononucleotide (NMN) Sales Value (2021-2032)
- 6.7.2 Europe Nicotinamide Mononucleotide (NMN) Sales Value Share by Country, 2025 VS 2032
- 6.8 Asia-Pacific
- 6.8.1 Asia-Pacific Nicotinamide Mononucleotide (NMN) Sales Value (2021-2032)
- 6.8.2 Asia-Pacific Nicotinamide Mononucleotide (NMN) Sales Value Share by Country, 2025 VS 2032
- 6.9 South America
- 6.9.1 South America Nicotinamide Mononucleotide (NMN) Sales Value (2021-2032)
- 6.9.2 South America Nicotinamide Mononucleotide (NMN) Sales Value Share by Country, 2025 VS 2032
- 6.10 Middle East & Africa
- 6.10.1 Middle East & Africa Nicotinamide Mononucleotide (NMN) Sales Value (2021-2032)
- 6.10.2 Middle East & Africa Nicotinamide Mononucleotide (NMN) Sales Value Share by Country, 2025 VS 2032
7 Nicotinamide Mononucleotide (NMN) Country-level Sales and Value Analysis
- 7.1 Global Nicotinamide Mononucleotide (NMN) Sales by Country: 2021 VS 2025 VS 2032
- 7.2 Global Nicotinamide Mononucleotide (NMN) Sales Value by Country: 2021 VS 2025 VS 2032
- 7.3 Global Nicotinamide Mononucleotide (NMN) Sales by Country (2021-2032)
- 7.3.1 Global Nicotinamide Mononucleotide (NMN) Sales by Country (2021-2026)
- 7.3.2 Global Nicotinamide Mononucleotide (NMN) Sales by Country (2027-2032)
- 7.4 Global Nicotinamide Mononucleotide (NMN) Sales Value by Country (2021-2032)
- 7.4.1 Global Nicotinamide Mononucleotide (NMN) Sales Value by Country (2021-2026)
- 7.4.2 Global Nicotinamide Mononucleotide (NMN) Sales Value by Country (2027-2032)
- 7.5 USA
- 7.5.1 USA Nicotinamide Mononucleotide (NMN) Sales Value Growth Rate (2021-2032)
- 7.5.2 USA Nicotinamide Mononucleotide (NMN) Sales Value Share by Type, 2025 VS 2032
- 7.5.3 USA Nicotinamide Mononucleotide (NMN) Sales Value Share by Application, 2025 VS 2032
- 7.6 Canada
- 7.6.1 Canada Nicotinamide Mononucleotide (NMN) Sales Value Growth Rate (2021-2032)
- 7.6.2 Canada Nicotinamide Mononucleotide (NMN) Sales Value Share by Type, 2025 VS 2032
- 7.6.3 Canada Nicotinamide Mononucleotide (NMN) Sales Value Share by Application, 2025 VS 2032
- 7.7 Mexico
- 7.6.1 Mexico Nicotinamide Mononucleotide (NMN) Sales Value Growth Rate (2021-2032)
- 7.6.2 Mexico Nicotinamide Mononucleotide (NMN) Sales Value Share by Type, 2025 VS 2032
- 7.6.3 Mexico Nicotinamide Mononucleotide (NMN) Sales Value Share by Application, 2025 VS 2032
- 7.8 Germany
- 7.8.1 Germany Nicotinamide Mononucleotide (NMN) Sales Value Growth Rate (2021-2032)
- 7.8.2 Germany Nicotinamide Mononucleotide (NMN) Sales Value Share by Type, 2025 VS 2032
- 7.8.3 Germany Nicotinamide Mononucleotide (NMN) Sales Value Share by Application, 2025 VS 2032
- 7.9 France
- 7.9.1 France Nicotinamide Mononucleotide (NMN) Sales Value Growth Rate (2021-2032)
- 7.9.2 France Nicotinamide Mononucleotide (NMN) Sales Value Share by Type, 2025 VS 2032
- 7.9.3 France Nicotinamide Mononucleotide (NMN) Sales Value Share by Application, 2025 VS 2032
- 7.10 U.K.
- 7.10.1 U.K. Nicotinamide Mononucleotide (NMN) Sales Value Growth Rate (2021-2032)
- 7.10.2 U.K. Nicotinamide Mononucleotide (NMN) Sales Value Share by Type, 2025 VS 2032
- 7.10.3 U.K. Nicotinamide Mononucleotide (NMN) Sales Value Share by Application, 2025 VS 2032
- 7.11 Italy
- 7.11.1 Italy Nicotinamide Mononucleotide (NMN) Sales Value Growth Rate (2021-2032)
- 7.11.2 Italy Nicotinamide Mononucleotide (NMN) Sales Value Share by Type, 2025 VS 2032
- 7.11.3 Italy Nicotinamide Mononucleotide (NMN) Sales Value Share by Application, 2025 VS 2032
- 7.12 Spain
- 7.12.1 Spain Nicotinamide Mononucleotide (NMN) Sales Value Growth Rate (2021-2032)
- 7.12.2 Spain Nicotinamide Mononucleotide (NMN) Sales Value Share by Type, 2025 VS 2032
- 7.12.3 Spain Nicotinamide Mononucleotide (NMN) Sales Value Share by Application, 2025 VS 2032
- 7.13 Russia
- 7.13.1 Russia Nicotinamide Mononucleotide (NMN) Sales Value Growth Rate (2021-2032)
- 7.13.2 Russia Nicotinamide Mononucleotide (NMN) Sales Value Share by Type, 2025 VS 2032
- 7.13.3 Russia Nicotinamide Mononucleotide (NMN) Sales Value Share by Application, 2025 VS 2032
- 7.14 Netherlands
- 7.14.1 Netherlands Nicotinamide Mononucleotide (NMN) Sales Value Growth Rate (2021-2032)
- 7.14.2 Netherlands Nicotinamide Mononucleotide (NMN) Sales Value Share by Type, 2025 VS 2032
- 7.14.3 Netherlands Nicotinamide Mononucleotide (NMN) Sales Value Share by Application, 2025 VS 2032
- 7.15 Nordic Countries
- 7.15.1 Nordic Countries Nicotinamide Mononucleotide (NMN) Sales Value Growth Rate (2021-2032)
- 7.15.2 Nordic Countries Nicotinamide Mononucleotide (NMN) Sales Value Share by Type, 2025 VS 2032
- 7.15.3 Nordic Countries Nicotinamide Mononucleotide (NMN) Sales Value Share by Application, 2025 VS 2032
- 7.16 China
- 7.16.1 China Nicotinamide Mononucleotide (NMN) Sales Value Growth Rate (2021-2032)
- 7.16.2 China Nicotinamide Mononucleotide (NMN) Sales Value Share by Type, 2025 VS 2032
- 7.16.3 China Nicotinamide Mononucleotide (NMN) Sales Value Share by Application, 2025 VS 2032
- 7.17 Japan
- 7.17.1 Japan Nicotinamide Mononucleotide (NMN) Sales Value Growth Rate (2021-2032)
- 7.17.2 Japan Nicotinamide Mononucleotide (NMN) Sales Value Share by Type, 2025 VS 2032
- 7.17.3 Japan Nicotinamide Mononucleotide (NMN) Sales Value Share by Application, 2025 VS 2032
- 7.18 South Korea
- 7.18.1 South Korea Nicotinamide Mononucleotide (NMN) Sales Value Growth Rate (2021-2032)
- 7.18.2 South Korea Nicotinamide Mononucleotide (NMN) Sales Value Share by Type, 2025 VS 2032
- 7.18.3 South Korea Nicotinamide Mononucleotide (NMN) Sales Value Share by Application, 2025 VS 2032
- 7.19 India
- 7.19.1 India Nicotinamide Mononucleotide (NMN) Sales Value Growth Rate (2021-2032)
- 7.19.2 India Nicotinamide Mononucleotide (NMN) Sales Value Share by Type, 2025 VS 2032
- 7.19.3 India Nicotinamide Mononucleotide (NMN) Sales Value Share by Application, 2025 VS 2032
- 7.20 Australia
- 7.20.1 Australia Nicotinamide Mononucleotide (NMN) Sales Value Growth Rate (2021-2032)
- 7.20.2 Australia Nicotinamide Mononucleotide (NMN) Sales Value Share by Type, 2025 VS 2032
- 7.20.3 Australia Nicotinamide Mononucleotide (NMN) Sales Value Share by Application, 2025 VS 2032
- 7.21 Southeast Asia
- 7.21.1 Southeast Asia Nicotinamide Mononucleotide (NMN) Sales Value Growth Rate (2021-2032)
- 7.21.2 Southeast Asia Nicotinamide Mononucleotide (NMN) Sales Value Share by Type, 2025 VS 2032
- 7.21.3 Southeast Asia Nicotinamide Mononucleotide (NMN) Sales Value Share by Application, 2025 VS 2032
- 7.22 Brazil
- 7.22.1 Brazil Nicotinamide Mononucleotide (NMN) Sales Value Growth Rate (2021-2032)
- 7.22.2 Brazil Nicotinamide Mononucleotide (NMN) Sales Value Share by Type, 2025 VS 2032
- 7.22.3 Brazil Nicotinamide Mononucleotide (NMN) Sales Value Share by Application, 2025 VS 2032
- 7.23 Argentina
- 7.23.1 Argentina Nicotinamide Mononucleotide (NMN) Sales Value Growth Rate (2021-2032)
- 7.23.2 Argentina Nicotinamide Mononucleotide (NMN) Sales Value Share by Type, 2025 VS 2032
- 7.23.3 Argentina Nicotinamide Mononucleotide (NMN) Sales Value Share by Application, 2025 VS 2032
- 7.24 Chile
- 7.24.1 Chile Nicotinamide Mononucleotide (NMN) Sales Value Growth Rate (2021-2032)
- 7.24.2 Chile Nicotinamide Mononucleotide (NMN) Sales Value Share by Type, 2025 VS 2032
- 7.24.3 Chile Nicotinamide Mononucleotide (NMN) Sales Value Share by Application, 2025 VS 2032
- 7.25 Colombia
- 7.25.1 Colombia Nicotinamide Mononucleotide (NMN) Sales Value Growth Rate (2021-2032)
- 7.25.2 Colombia Nicotinamide Mononucleotide (NMN) Sales Value Share by Type, 2025 VS 2032
- 7.25.3 Colombia Nicotinamide Mononucleotide (NMN) Sales Value Share by Application, 2025 VS 2032
- 7.26 Peru
- 7.26.1 Peru Nicotinamide Mononucleotide (NMN) Sales Value Growth Rate (2021-2032)
- 7.26.2 Peru Nicotinamide Mononucleotide (NMN) Sales Value Share by Type, 2025 VS 2032
- 7.26.3 Peru Nicotinamide Mononucleotide (NMN) Sales Value Share by Application, 2025 VS 2032
- 7.27 Saudi Arabia
- 7.27.1 Saudi Arabia Nicotinamide Mononucleotide (NMN) Sales Value Growth Rate (2021-2032)
- 7.27.2 Saudi Arabia Nicotinamide Mononucleotide (NMN) Sales Value Share by Type, 2025 VS 2032
- 7.27.3 Saudi Arabia Nicotinamide Mononucleotide (NMN) Sales Value Share by Application, 2025 VS 2032
- 7.28 Israel
- 7.28.1 Israel Nicotinamide Mononucleotide (NMN) Sales Value Growth Rate (2021-2032)
- 7.28.2 Israel Nicotinamide Mononucleotide (NMN) Sales Value Share by Type, 2025 VS 2032
- 7.28.3 Israel Nicotinamide Mononucleotide (NMN) Sales Value Share by Application, 2025 VS 2032
- 7.29 UAE
- 7.29.1 UAE Nicotinamide Mononucleotide (NMN) Sales Value Growth Rate (2021-2032)
- 7.29.2 UAE Nicotinamide Mononucleotide (NMN) Sales Value Share by Type, 2025 VS 2032
- 7.29.3 UAE Nicotinamide Mononucleotide (NMN) Sales Value Share by Application, 2025 VS 2032
- 7.30 Turkey
- 7.30.1 Turkey Nicotinamide Mononucleotide (NMN) Sales Value Growth Rate (2021-2032)
- 7.30.2 Turkey Nicotinamide Mononucleotide (NMN) Sales Value Share by Type, 2025 VS 2032
- 7.30.3 Turkey Nicotinamide Mononucleotide (NMN) Sales Value Share by Application, 2025 VS 2032
- 7.31 Iran
- 7.31.1 Iran Nicotinamide Mononucleotide (NMN) Sales Value Growth Rate (2021-2032)
- 7.31.2 Iran Nicotinamide Mononucleotide (NMN) Sales Value Share by Type, 2025 VS 2032
- 7.31.3 Iran Nicotinamide Mononucleotide (NMN) Sales Value Share by Application, 2025 VS 2032
- 7.32 Egypt
- 7.32.1 Egypt Nicotinamide Mononucleotide (NMN) Sales Value Growth Rate (2021-2032)
- 7.32.2 Egypt Nicotinamide Mononucleotide (NMN) Sales Value Share by Type, 2025 VS 2032
- 7.32.3 Egypt Nicotinamide Mononucleotide (NMN) Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
- 8.1 GeneHarbor
- 8.1.1 GeneHarbor Company Information
- 8.1.2 GeneHarbor Business Overview
- 8.1.3 GeneHarbor Nicotinamide Mononucleotide (NMN) Sales, Value and Gross Margin (2021-2026)
- 8.1.4 GeneHarbor Nicotinamide Mononucleotide (NMN) Product Portfolio
- 8.1.5 GeneHarbor Recent Developments
- 8.2 Herbalmax
- 8.2.1 Herbalmax Company Information
- 8.2.2 Herbalmax Business Overview
- 8.2.3 Herbalmax Nicotinamide Mononucleotide (NMN) Sales, Value and Gross Margin (2021-2026)
- 8.2.4 Herbalmax Nicotinamide Mononucleotide (NMN) Product Portfolio
- 8.2.5 Herbalmax Recent Developments
- 8.3 Genex Formulas
- 8.3.1 Genex Formulas Company Information
- 8.3.2 Genex Formulas Business Overview
- 8.3.3 Genex Formulas Nicotinamide Mononucleotide (NMN) Sales, Value and Gross Margin (2021-2026)
- 8.3.4 Genex Formulas Nicotinamide Mononucleotide (NMN) Product Portfolio
- 8.3.5 Genex Formulas Recent Developments
- 8.4 MIRAILAB BIOSCIENCE Inc
- 8.4.1 MIRAILAB BIOSCIENCE Inc Company Information
- 8.4.2 MIRAILAB BIOSCIENCE Inc Business Overview
- 8.4.3 MIRAILAB BIOSCIENCE Inc Nicotinamide Mononucleotide (NMN) Sales, Value and Gross Margin (2021-2026)
- 8.4.4 MIRAILAB BIOSCIENCE Inc Nicotinamide Mononucleotide (NMN) Product Portfolio
- 8.4.5 MIRAILAB BIOSCIENCE Inc Recent Developments
- 8.5 Maac10 Formulas
- 8.5.1 Maac10 Formulas Company Information
- 8.5.2 Maac10 Formulas Business Overview
- 8.5.3 Maac10 Formulas Nicotinamide Mononucleotide (NMN) Sales, Value and Gross Margin (2021-2026)
- 8.5.4 Maac10 Formulas Nicotinamide Mononucleotide (NMN) Product Portfolio
- 8.5.5 Maac10 Formulas Recent Developments
- 8.6 EffePharm
- 8.6.1 EffePharm Company Information
- 8.6.2 EffePharm Business Overview
- 8.6.3 EffePharm Nicotinamide Mononucleotide (NMN) Sales, Value and Gross Margin (2021-2026)
- 8.6.4 EffePharm Nicotinamide Mononucleotide (NMN) Product Portfolio
- 8.6.5 EffePharm Recent Developments
- 8.7 Bontac
- 8.7.1 Bontac Company Information
- 8.7.2 Bontac Business Overview
- 8.7.3 Bontac Nicotinamide Mononucleotide (NMN) Sales, Value and Gross Margin (2021-2026)
- 8.7.4 Bontac Nicotinamide Mononucleotide (NMN) Product Portfolio
- 8.7.5 Bontac Recent Developments
- 8.8 CELFULL
- 8.8.1 CELFULL Company Information
- 8.8.2 CELFULL Business Overview
- 8.8.3 CELFULL Nicotinamide Mononucleotide (NMN) Sales, Value and Gross Margin (2021-2026)
- 8.8.4 CELFULL Nicotinamide Mononucleotide (NMN) Product Portfolio
- 8.8.5 CELFULL Recent Developments
- 8.9 Kingdomway
- 8.9.1 Kingdomway Company Information
- 8.9.2 Kingdomway Business Overview
- 8.9.3 Kingdomway Nicotinamide Mononucleotide (NMN) Sales, Value and Gross Margin (2021-2026)
- 8.9.4 Kingdomway Nicotinamide Mononucleotide (NMN) Product Portfolio
- 8.9.5 Kingdomway Recent Developments
- 8.10 Oriental Yeast
- 8.10.1 Oriental Yeast Company Information
- 8.10.2 Oriental Yeast Business Overview
- 8.10.3 Oriental Yeast Nicotinamide Mononucleotide (NMN) Sales, Value and Gross Margin (2021-2026)
- 8.10.4 Oriental Yeast Nicotinamide Mononucleotide (NMN) Product Portfolio
- 8.10.5 Oriental Yeast Recent Developments
- 8.11 Blue California (Conagen)
- 8.11.1 Blue California (Conagen) Company Information
- 8.11.2 Blue California (Conagen) Business Overview
- 8.11.3 Blue California (Conagen) Nicotinamide Mononucleotide (NMN) Sales, Value and Gross Margin (2021-2026)
- 8.11.4 Blue California (Conagen) Nicotinamide Mononucleotide (NMN) Product Portfolio
- 8.11.5 Blue California (Conagen) Recent Developments
- 8.12 Borealis Pharma B.V. (Longevir®)
- 8.12.1 Borealis Pharma B.V. (Longevir®) Company Information
- 8.12.2 Borealis Pharma B.V. (Longevir®) Business Overview
- 8.12.3 Borealis Pharma B.V. (Longevir®) Nicotinamide Mononucleotide (NMN) Sales, Value and Gross Margin (2021-2026)
- 8.12.4 Borealis Pharma B.V. (Longevir®) Nicotinamide Mononucleotide (NMN) Product Portfolio
- 8.12.5 Borealis Pharma B.V. (Longevir®) Recent Developments
9 Value Chain and Sales Channels Analysis
- 9.1 Nicotinamide Mononucleotide (NMN) Value Chain Analysis
- 9.1.1 Nicotinamide Mononucleotide (NMN) Key Raw Materials
- 9.1.2 Raw Materials Key Suppliers
- 9.1.3 Manufacturing Cost Structure
- 9.1.4 Nicotinamide Mononucleotide (NMN) Sales Mode & Process
- 9.2 Nicotinamide Mononucleotide (NMN) Sales Channels Analysis
- 9.2.1 Direct Comparison with Distribution Share
- 9.2.2 Nicotinamide Mononucleotide (NMN) Distributors
- 9.2.3 Nicotinamide Mononucleotide (NMN) Customers
10 Concluding Insights
11 Appendix
- 11.1 Reasons for Doing This Study
- 11.2 Research Methodology
- 11.3 Research Process
- 11.4 Authors List of This Report
- 11.5 Data Source
- 11.5.1 Secondary Sources
- 11.5.2 Primary Sources
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst